Comparing Cibinqo vs Rinvoq
| Cibinqo (abrocitinib) | Rinvoq (upadacitinib) |
|
|---|
| Cibinqo (abrocitinib) | Rinvoq (upadacitinib) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Atopic Dermatitis. Cibinqo may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Crohn's Disease, Ankylosing Spondylitis, Atopic Dermatitis, Non-Radiographic Axial Spondyloarthritis, Giant Cell Arteritis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic... View more |
Related suggestions Atopic Dermatitis
|
|||||||||||||||
| More about Cibinqo (abrocitinib) | More about Rinvoq (upadacitinib) | ||||||||||||||||
| Ratings & Reviews | |||||||||||||||||
|
Cibinqo has an average rating of 8.2 out of 10 from a total of 6 ratings on Drugs.com. 67% of reviewers reported a positive effect, while 0% reported a negative effect. |
Rinvoq has an average rating of 7.0 out of 10 from a total of 231 ratings on Drugs.com. 56% of reviewers reported a positive effect, while 17% reported a negative effect. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||||||||||
|
View all Cibinqo side effects |
View all Rinvoq side effects |
||||||||||||||||
| Drug Class | |||||||||||||||||
| Generic Availability | |||||||||||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||||||||||
View all Cibinqo prices |
View all Rinvoq prices |
||||||||||||||||
| Dosage Forms | |||||||||||||||||
|
|
||||||||||||||||
| Brand Names | |||||||||||||||||
|
N/A |
Other upadacitinib brands include: Rinvoq LQ | ||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||||||||||
|
5 hours |
14 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | |||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | |||||||||||||||||
|
A total of 581 drugs are known to interact with Cibinqo:
|
A total of 613 drugs are known to interact with Rinvoq:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||||||||||
|
|
||||||||||||||||
| Disease Interactions | |||||||||||||||||
| First Approval Date | |||||||||||||||||
|
January 14, 2022 |
August 16, 2019 |
||||||||||||||||
| WADA Class View classifications | |||||||||||||||||
|
N/A |
N/A |
||||||||||||||||
| More Information | |||||||||||||||||
| Patient Resources | |||||||||||||||||
| Professional Resources | |||||||||||||||||
| Related Treatment Guide | |||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Opzelura
Opzelura is used to treat atopic dermatitis (eczema) and nonsegmental vitiligo. It is a topical ...
Eucrisa
Eucrisa (crisaborole) is used to treat mild to moderate eczema (atopic dermatitis) Includes Eucrisa ...
Adbry
Adbry is used to treat moderate-to-severe atopic dermatitis (eczema) in adults and children aged 12 ...
Dupixent
Dupixent is used to treat eczema, eosinophilic or oral-corticosteroid-dependent asthma, chronic ...
Temovate
Temovate is used for atopic dermatitis, dermatitis, dermatological disorders, eczema, lichen ...
Lidex
Lidex is used for atopic dermatitis, dermatitis, eczema, psoriasis
Clobex
Clobex is used for atopic dermatitis, dermatitis, dermatological disorders, eczema, lichen planus ...
Olux
Olux is used for atopic dermatitis, dermatitis, dermatological disorders, eczema, lichen planus ...
Lidex-E
Lidex-E is used for atopic dermatitis, dermatitis, eczema, psoriasis
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.